Q-omics provides the consensus-scored CEACAM7 profile across patient tissues and cancer cell-line models. CEACAM7 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, CEACAM7 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, CEACAM7 RNA expression shows 9,547 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight KIRP, COAD, and BRCA as cancer lineages where CEACAM7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CEACAM7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CEACAM7 survival associations across molecular data types. CEACAM7 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (3) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CEACAM7 RNA expression–survival associations across cancer types. High CEACAM7 expression shows unfavorable associations in KIRP, KIRC, THCA, DLBC and LUAD, but favorable associations in HNSC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for CEACAM7 RNA expression.
This table summarizes CEACAM7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for CEACAM7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CEACAM7 shows lower tumor expression in COAD, HNSC, KIRC and THCA and higher tumor expression in LUAD and BRCA. The COAD box plot shows higher CEACAM7 RNA expression in normal versus tumor tissue (log2 FC = −5.772, t-test p < 0.001).
This table shows molecular features associated with CEACAM7 in patient tissues and cancer cell lines. In patient samples, CEACAM7 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, CEACAM7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and LARGE_INTESTINE.
